©TheCanadian Journal ofUrology™: International Supplement, April 2014
30.BanderNH.Technology insight:monoclonalantibody imaging
of prostate cancer.
NatClinPractUrol
2006;3(4):216-225.
31.Pandit-Taskar N, O’Donoghue JA, MorrisMJ et al. Antibody
mass escalation study in patients with castration-resistant
prostate cancer using 111In-J591: lesion detectability and
dosimetricprojections for90Yradioimmunotherapy.
JNuclMed
2008;49(7):1066-1074.
32.Osborne JR, Akhtar NH, Vallabhajosula S, AnandA, Deh K,
TagawaST.Prostate-specificmembraneantigen-based imaging.
UrolOncol
2013;31(2):144-154.
33.Evans MJ, Smith-Jones PM, Wongvipat J et al. Noninvasive
measurement of androgen receptor signaling with a positron-
emitting radiopharmaceutical that targets prostate-specific
membraneantigen.
ProcNatlAcadSciUSA
2011;108(23):9578-9582.
34.Afshar-OromiehA,HaberkornU,HadaschikBetal.PET/MRI
witha (68)Ga-PSMAligand for thedetectionof prostatecancer.
Eur JNuclMedMol Imaging
2013;40(10):1629-1630.
35.Afshar-OromiehA,ZechmannCM,MalcherAetal.Comparison
of PET imagingwith a (68)Ga-labelledPSMA ligand and (18)
F-choline-basedPET/CT for thediagnosisofrecurrentprostate
cancer.
Eur JNuclMedMol Imaging
2014;41(1):11-20.
36.Barrett T, Gill AB, Kataoka MY et al. DCE and DWMRI in
monitoring response to androgen deprivation therapy in
patientswithprostatecancer:afeasibilitystudy.
MagnResonMed
2012;67(3):778-785.
37.MichouxN, Simoni P, Tombal B et al. EvaluationofDCE-MRI
post-processing techniques toassessmetastaticbonemarrow in
patientswithprostate cancer.
Clin Imaging
2012;36(4):308-315.
38.Luboldt W, Kufer R, Blumstein N et al. Prostate carcinoma:
diffusion weighted imaging as potential alternative to
conventional MR and 11C-choline PET/CT for detection of
bonemetastases.
Radiology
2008;249(3):1017-1025.
39.NakanishiK,KobayashiM,NakaguchiKetal.Whole-bodyMRI
fordetectingmetastaticbonetumor:diagnosticvalueofdiffusion-
weighted images.
MagnResonMedSci
2007;6(3):147-155.
40.Lecouvet FE, ElMouedden J, ColletteLet al. Canwhole-body
magneticresonance imagingwithdiffusion-weighted imaging
replaceTc-99mbone scanning and computed tomography for
single-step detection of metastases in patients with high-risk
prostate cancer?
EurUrol
2012;62(1):68-75.
41.LeeKC,BradleyDA,HussainMetal.Afeasibilitystudyevaluating
the functional diffusionmap as apredictive imagingbiomarker
for detection of treatment response in a patient withmetastatic
prostatecancer to thebone.
Neoplasia
2007;9(12):1003-1011.
42.Reischauer C, Froehlich JM, Koh DM et al. Bone metastases
from prostate cancer: assessing treatment response by using
diffusion-weighted imaging and functional diffusion maps:
initial observations.
Radiology
2010;257(2):523-531.
43.MessiouC,CollinsDJ,GilesSetal.Assessing response inbone
metastases in prostate cancer with diffusion weightedMRI.
EurRadiol
2011;21(10):2169-2177.
44.NelsonSJ,Kurhanewicz J,VigneronDBetal.Metabolic imaging
of patientswithprostate cancer usinghyperpolarized [1-13C]
pyruvate.
Sci TranslMed
2013;5(198):198ra108.
45.Scher HI, Halabi S, Tannock I et al. Prostate Cancer Clinical
TrialsWorkingGroup. Design and end points of clinical trials
forpatientswithprogressiveprostatecancerandcastrate levels
oftestosterone: recommendationsoftheProstateCancerClinical
TrialsWorkingGroup.
JClinOncol
2008;26(7):1148-1159.
47
LeungETAL.
